Dr McNamee has deep executive experience in the biopharmaceutical industry, with a focus on strategy and creating long‑term shareholder value. Dr McNamee was the Chief Executive Officer and Managing Director of CSL from 1990 until 2013. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued a number of private equity interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government’s Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. Other directorships and offices (current and recent): • Director Golf Preserve Pty Ltd (since February 2025); and • Former Chair of the Geoff Ogilvy Foundation (from May 2021 to February 2025). Board Committee memberships: • Member of the Innovation and Development Committee; • Member of the Disclosure Committee; and • Member of the Corporate Governance and Nomination Committee. Brian McNamee AO MBBS, FTSE Age 69 Chair and Independent Non-executive Director Director of CSL Limited since February 2018 and Chair from October 2018. Gordon Naylor BE (Hons), Grad Dip (Computer Science), MBA, CPA, GAICD, FTSE Age 63 CEO and MD (Non-independent Executive Director) Director of CSL Limited since December 2025 and appointed Interim Chief Executive Officer and Managing Director in February 2026. Andrew Cuthbertson AO BMedSci, MBBS, PhD, FAA, FTSE, FAHMS Age 71 Independent Non-executive Director Director of CSL Limited since October 2018, and a Non‑executive Director since October 2021. Mr Naylor was appointed Interim Chief Executive Officer and Managing Director of CSL Limited on 11 February 2026. Mr Naylor is a seasoned global biotechnology executive with more than three decades of leadership experience across operations, finance, IT and advanced manufacturing. Beginning his career as an engineer, he joined CSL in the late 1980s and played a pivotal role in the Company’s transformation from an Australian Government Department into a global biotechnology leader. Over his 33-year tenure at CSL, Mr Naylor held a range of senior executive roles across multiple countries, including Chief Financial Officer and later President of Seqirus, where he led the successful three-year turnaround that positioned the business as a global influenza vaccines leader. His contributions spanned the design and build of major manufacturing infrastructure, the global expansion of CSL Plasma, leadership of global supply chain and IT functions, and responsibility for several of the Company’s most significant international acquisitions. Following his long executive career, Mr Naylor was appointed to the CSL Board in December 2025, continuing his long association with the Company through strategic governance and leadership. Mr Naylor holds a Bachelor of Engineering (Hons), a Graduate Diploma in Computer Science, an MBA from Melbourne Business School, is a graduate of the Australian Institute of Company Directors, is a fellow of the Australian Academy of Technological Sciences and Engineering and a Certified Practising Accountant. Other directorships and offices (current and recent): • Director of Orica Limited (since April 2022). Board Committee memberships: • Member of the Innovation and Development Committee; and • Member of the Disclosure Committee. Professor Cuthbertson has over 35 years’ experience in medical research and biotech development with large biopharmaceutical companies and medical organisations. He also has non-executive director experience. Professor Cuthbertson joined CSL in April 1997 as the Director of Research. Prior to CSL, he was a senior scientist at Genentech Inc., a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicine for people with life-threatening diseases. After completing medical training at the University of Melbourne and a PhD in immunology at The Walter and Eliza Hall Institute of Medical Research in Australia, Professor Cuthbertson spent five years working in molecular biology research as a staff member at the Howard Florey Institute in Melbourne, Australia, and the National Institutes of Health in Maryland, United States. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. Other directorships and offices (current and recent): • Chair of the interim Scientific Advisory Board for the Cumming Global Centre for Pandemic Therapeutics (since August 2023); • Deputy Chancellor of the University of Melbourne (since January 2023); • Member of The University of Melbourne Council (since January 2020); • Director of the Grattan Institute (since January 2019); and • Director of the Centre of Eye Research Australia (since March 2017). Board Committee memberships: • Chair of the Innovation and Development Committee; and • Member of the Corporate Governance and Nomination Committee. Board of Directors 42 Governance
RkJQdWJsaXNoZXIy MjE2NDg3